Source link : https://www.newshealth.biz/health-news/fda-expands-enhertu-approval-to-her2-ultralow-breast-cancer/
(MedPage Today) — The FDA expanded the approval of trastuzumab deruxtecan (T-DXd, Enhertu) to include treatment of unresectable/metastatic hormone receptor (HR)-positive, HER2-low/ultralow breast cancer. Approval stipulates use in patients with… Source link : https://www.medpagetoday.com/hematologyoncology/breastcancer/113982 Author : Publish date : 2025-01-28 20:41:44 Copyright for syndicated content belongs to the linked Source.
Author : News Health
Publish date : 2025-01-28 20:41:44
Copyright for syndicated content belongs to the linked Source.